24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)
Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD. Background: HD…Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Efficacy of perampanel in paroxysmal kinesigenic dyskinesia
Objective: To explore the efficacy and safety of perampanel in the treatment of paroxysmal kinesigenic dyskinesia (PKD) Background: Perampanel is a new type of antiepileptic…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…A Retrospective Review of Amantadine in Progressive Supranuclear Palsy
Objective: To determine the efficacy and tolerability of amantadine in Progressive supranuclear palsy (PSP). Background: PSP is one of the most common atypical parkinsonian disorders,…Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking
Objective: Based on the method of network pharmacology, this paper discusses the potential effects and mechanisms of SGD in the treatment of pain in PD. Background:…Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of L-3,4-dihydroxyphenylalanine (L-DOPA) in the common marmoset (Callithrix jacchus). Background: The common marmoset has been used to model…Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers
Objective: A survey of neurology Advanced Practice Providers (APPs) provides insights into their perspectives on managing and treating patients with Parkinson’s disease (PD) in the…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 36
- Next Page »